Marktanalyse - Pancreatic Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
2006 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Pancreatic Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer — Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer Overview 15

Therapeutics Development 16

Pancreatic Cancer - Therapeutics under Development by Companies 18

Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 45

Pancreatic Cancer - Pipeline Products Glance 49

Pancreatic Cancer - Products under Development by Companies 53

Pancreatic Cancer - Products under Investigation by Universities/Institutes 88

Pancreatic Cancer - Companies Involved in Therapeutics Development 93

Pancreatic Cancer - Therapeutics Assessment 397

Drug Profiles 478

Pancreatic Cancer - Dormant Projects 1889

Pancreatic Cancer - Discontinued Products 1922

Pancreatic Cancer - Product Development Milestones 1929

Appendix 1942





List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 82

Number of Products under Development by Companies, H2 2016 (Contd..1) 83

Number of Products under Development by Companies, H2 2016 (Contd..2) 84

Number of Products under Development by Companies, H2 2016 (Contd..3) 85

Number of Products under Development by Companies, H2 2016 (Contd..4) 86

Number of Products under Development by Companies, H2 2016 (Contd..5) 87

Number of Products under Development by Companies, H2 2016 (Contd..6) 88

Number of Products under Development by Companies, H2 2016 (Contd..7) 89

Number of Products under Development by Companies, H2 2016 (Contd..8) 90

Number of Products under Development by Companies, H2 2016 (Contd..9) 91

Number of Products under Development by Companies, H2 2016 (Contd..10) 92

Number of Products under Development by Companies, H2 2016 (Contd..11) 93

Number of Products under Development by Companies, H2 2016 (Contd..12) 94

Number of Products under Development by Companies, H2 2016 (Contd..13) 95

Number of Products under Development by Companies, H2 2016 (Contd..14) 96

Number of Products under Development by Companies, H2 2016 (Contd..15) 97

Number of Products under Development by Companies, H2 2016 (Contd..16) 98

Number of Products under Development by Companies, H2 2016 (Contd..17) 99

Number of Products under Development by Companies, H2 2016 (Contd..18) 100

Number of Products under Development by Companies, H2 2016 (Contd..19) 101

Number of Products under Development by Companies, H2 2016 (Contd..20) 102

Number of Products under Development by Companies, H2 2016 (Contd..21) 103

Number of Products under Development by Companies, H2 2016 (Contd..22) 104

Number of Products under Development by Companies, H2 2016 (Contd..23) 105

Number of Products under Development by Companies, H2 2016 (Contd..24) 106

Number of Products under Development by Companies, H2 2016 (Contd..25) 107

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 109

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 110

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 111

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Development, H2 2016 114

Comparative Analysis by Unknown Stage Development, H2 2016 115

Products under Development by Companies, H2 2016 116

Products under Development by Companies, H2 2016 (Contd..1) 117

Products under Development by Companies, H2 2016 (Contd..2) 118

Products under Development by Companies, H2 2016 (Contd..3) 119

Products under Development by Companies, H2 2016 (Contd..4) 120

Products under Development by Companies, H2 2016 (Contd..5) 121

Products under Development by Companies, H2 2016 (Contd..6) 122

Products under Development by Companies, H2 2016 (Contd..7) 123

Products under Development by Companies, H2 2016 (Contd..8) 124

Products under Development by Companies, H2 2016 (Contd..9) 125

Products under Development by Companies, H2 2016 (Contd..10) 126

Products under Development by Companies, H2 2016 (Contd..11) 127

Products under Development by Companies, H2 2016 (Contd..12) 128

Products under Development by Companies, H2 2016 (Contd..13) 129

Products under Development by Companies, H2 2016 (Contd..14) 130

Products under Development by Companies, H2 2016 (Contd..15) 131

Products under Development by Companies, H2 2016 (Contd..16) 132

Products under Development by Companies, H2 2016 (Contd..17) 133

Products under Development by Companies, H2 2016 (Contd..18) 134

Products under Development by Companies, H2 2016 (Contd..19) 135

Products under Development by Companies, H2 2016 (Contd..20) 136

Products under Development by Companies, H2 2016 (Contd..21) 137

Products under Development by Companies, H2 2016 (Contd..22) 138

Products under Development by Companies, H2 2016 (Contd..23) 139

Products under Development by Companies, H2 2016 (Contd..24) 140

Products under Development by Companies, H2 2016 (Contd..25) 141

Products under Development by Companies, H2 2016 (Contd..26) 142

Products under Development by Companies, H2 2016 (Contd..27) 143

Products under Development by Companies, H2 2016 (Contd..28) 144

Products under Development by Companies, H2 2016 (Contd..29) 145

Products under Development by Companies, H2 2016 (Contd..30) 146

Products under Development by Companies, H2 2016 (Contd..31) 147

Products under Development by Companies, H2 2016 (Contd..32) 148

Products under Development by Companies, H2 2016 (Contd..33) 149

Products under Development by Companies, H2 2016 (Contd..34) 150

Products under Investigation by Universities/Institutes, H2 2016 151

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 152

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 153

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 154

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 155

Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 156

Pancreatic Cancer - Pipeline by 4SC AG, H2 2016 157

Pancreatic Cancer - Pipeline by AB Science SA, H2 2016 158

Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016 159

Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016 160

Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 161

Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 162

Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016 163

Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 164

Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016 165

Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016 166

Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016 167

Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016 168

Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016 169

Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 170

Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016 171

Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016 172

Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016 173

Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016 174

Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016 175

Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016 176

Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016 177

Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 178

Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016 179

Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 180

Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 181

Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016 182

Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016 183

Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016 184

Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016 185

Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016 186

Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016 187

Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016 188

Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 189

Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016 190

Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016 191

Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192

Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016 193

Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 194

Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 195

Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 196

Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 197

Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 198

Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 199

Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200

Pancreatic Cancer - Pipeline by Bayer AG, H2 2016 201

Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016 202

Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 203

Pancreatic Cancer - Pipeline by Berg LLC, H2 2016 204

Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016 205

Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 206

Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 207

Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 208

Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 209

Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016 210

Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016 211

Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016 212

Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 213

Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016 214

Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016 215

Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016 216

Pancreatic Cancer - Pipeline by Biotest AG, H2 2016 217

Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016 218

Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016 219

Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220

Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221

Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222

Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016 223

Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 224

Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016 225

Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 226

Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016 227

Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016 228

Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016 229

Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 230

Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016 231

Pancreatic Cancer - Pipeline by Celyad SA, H2 2016 232

Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016 233

Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016 234

Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016 235

Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 236

Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 237

Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016 238

Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 239

Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016 240

Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016 241

Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242

Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 243

Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016 244

Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016 245

Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 246

Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 247





List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2016 79

Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80

Number of Products under Development by Companies, H2 2016 81

Number of Products under Investigation by Universities/Institutes, H2 2016 108

Comparative Analysis by Late Stage Development, H2 2016 112

Comparative Analysis by Clinical Stage Development, H2 2016 113

Comparative Analysis by Early Stage Products, H2 2016 114

Assessment by Monotherapy Products, H2 2016 460

Assessment by Combination Products, H2 2016 461

Number of Products by Top 10 Targets, H2 2016 462

Number of Products by Stage and Top 10 Targets, H2 2016 462

Number of Products by Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504

Number of Products by Top 10 Routes of Administration, H2 2016 537

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 537

Number of Products by Top 10 Molecule Types, H2 2016 539

Number of Products by Stage and Top 10 Molecule Types, H2 2016 539

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus